{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals Hits New 52-Week Low at $6.00
BioCryst Pharmaceuticals has hit a new 52-week low, trading at USD 6.00. The company, with a market cap of USD 1,719 million, has faced a performance dip over the past year. Despite a significant increase in operating profit and positive cash flow, promoter confidence has waned, complicating its market outlook.
BioCryst Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Volatility
BioCryst Pharmaceuticals, Inc. has seen its stock price decline to $7.02, down from $7.15. The company has experienced significant volatility over the past year, with a 52-week high of $11.31 and a low of $6.01. Current technical indicators suggest a bearish sentiment, and the stock has underperformed relative to the S&P 500.
Is BioCryst Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, BioCryst Pharmaceuticals, Inc. is in a bearish trend with weak strength indicators, having underperformed the S&P 500 significantly over various periods, including a 1-week return of -6.29% compared to the S&P's 1.09%.
Is BioCryst Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, BioCryst Pharmaceuticals, Inc. is in a bearish trend with weak strength, indicated by bearish MACD readings and underperformance of 6.29% over the past week and 13.75% over the past month compared to the S&P 500.
Is BioCryst Pharmaceuticals, Inc. technically bullish or bearish?
As of September 11, 2025, BioCryst Pharmaceuticals, Inc. is in a mildly bearish trend, indicated by bearish MACD and moving averages, underperforming the S&P 500 with recent returns of -1.36% and -5.01%, while year-to-date it has a positive return of 5.85%.
Is BioCryst Pharmaceuticals, Inc. technically bullish or bearish?
As of May 1, 2025, BioCryst Pharmaceuticals, Inc. shows a bullish trend supported by strong MACD and KST indicators, although Dow Theory presents a mixed view.
Who are in the management team of BioCryst Pharmaceuticals, Inc.?
As of March 2022, the management team of BioCryst Pharmaceuticals, Inc. includes Robert Ingram (Independent Chairman), Jon Stonehouse (CEO), and several independent directors: George Abercrombie, Stephen Aselage, Theresa Heggie, Nancy Hutson, and Kenneth Lee. They oversee the company's strategic direction and operations.
What does BioCryst Pharmaceuticals, Inc. do?
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing small molecule drugs for rare diseases. It has a market cap of approximately $2.09 billion, with recent net sales of $146 million and no net profit.
How big is BioCryst Pharmaceuticals, Inc.?
As of Jun 18, BioCryst Pharmaceuticals, Inc. has a market capitalization of $2.09 billion, with recent net sales of $503.47 million and a net profit of -$53.47 million. As of Dec 24, the company reported shareholder's funds of -$475.93 million and total assets of $490.42 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
